Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research note issued to investors on Friday,RTT News reports. They currently have a $23.00 price target on the stock. Wedbush’s target price suggests a potential upside of 233.82% from the stock’s current price.

YMAB has been the topic of a number of other research reports. Brookline Capital Management started coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price on the stock. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock opened at $6.89 on Friday. Y-mAbs Therapeutics has a 12 month low of $6.84 and a 12 month high of $20.90. The stock has a market capitalization of $308.60 million, a price-to-earnings ratio of -12.76 and a beta of 0.69. The firm’s fifty day simple moving average is $10.32 and its 200-day simple moving average is $12.13.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the company posted ($0.18) EPS. Analysts anticipate that Y-mAbs Therapeutics will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in the stock. State Street Corp boosted its holdings in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after acquiring an additional 47,846 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Y-mAbs Therapeutics in the third quarter valued at $133,000. SG Americas Securities LLC acquired a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth $178,000. Finally, Squarepoint Ops LLC increased its holdings in Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after acquiring an additional 74,452 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.